LENZ Therapeutics (LENZ) Amortizatization of Intangibles (2022 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Amortizatization of Intangibles of $316000.0 for Q1 2026, down 72.13% year-over-year from $1.1 million in Q1 2025, and down 48.03% quarter-over-quarter from $608000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Amortizatization of Intangibles for 5 consecutive years, with $316000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 72.13% year-over-year to $316000.0; the TTM figure through Mar 2026 stood at $2.6 million (down 46.86% YoY), while the FY2025 annual figure was $3.4 million, down 15.14% from the prior year.
- Amortizatization of Intangibles retreated to $316000.0 in Q1 2026 per LENZ's latest filing, from $608000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.4 million in Q4 2024 and bottomed at -$45000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $649937.5 across 5 years, with a median of $585000.0 in 2022.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles surged 4947.37% — and 2026, when it slumped 72.13%.
- LENZ Therapeutics' Amortizatization of Intangibles stood at $1.1 million in 2022, then plunged by 54.42% to $511000.0 in 2023, then surged by 178.67% to $1.4 million in 2024, then plunged by 57.3% to $608000.0 in 2025, then slumped by 48.03% to $316000.0 in 2026.
- Business Quant data shows LENZ's Amortizatization of Intangibles at $316000.0 in Q1 2026, $608000.0 in Q4 2025, and $779000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 131,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 131,000.00 |
| Jun 30, 2026 | 131,000.00 |
| Mar 31, 2026 | 316,000.00 |
| Mar 31, 2026 | 316,000.00 |
| Dec 31, 2025 | 608,000.00 |
| Dec 31, 2025 | 608,000.00 |
| Sep 30, 2025 | 779,000.00 |
| Sep 30, 2025 | 779,000.00 |
| Jun 30, 2025 | 888,000.00 |
| Jun 30, 2025 | 888,000.00 |
| Mar 31, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 959,000.00 |
| Jun 30, 2024 | 959,000.00 |
| Mar 31, 2024 | 275,000.00 |
| Mar 31, 2024 | 275,000.00 |